DCGI Approves Single-Dose Sputnik Light COVID-19 Vaccine for Phase 3 Trials in India

DCGI Approves Single-Dose Sputnik Light COVID-19 Vaccine for Phase 3 Trials in India

New Delhi, September 15: The Drug Controller General of India has given its approval to the single-dose COVID-19 vaccine version of the Sputnik V vaccine ‘Sputnik Light’ to conduct trials on the Indian population to check whether the vaccine gives a similar immune response in trials similar to what it has shown on the Russian population.

A Subject Expert Committee (SEC) meeting held on August 5 recommended the trial condition based on the efficacy of the vaccine also to be evaluated on the 42nd, 90th, and 180th day following the second dose. Also Read | MG Astor Mid-Size SUV Officially Revealed, India Launch This Festive Season.

“Interim analysis can be conducted on day 42 as this data was generated during the Sputnik V trials in India after the first dose, which was stated to be available up to day 21,” reads the minutes of the meeting. Also Read | 2021 Force Gurkha SUV Unveiled in India; Check Features & Specifications Here.

Earlier in the month of April, the two-dose version of the vaccine, Sputnik V, was approved for ’emergency use’ by the Drugs Controller General of India (DCGI).

According to Dr V K Paul, Member (Health), NITI Aayog, till now 8- 9 lakh doses of Sputnik V has been administered in India. Sputnik Light, which is the first dose of the original two-dose composition, has shown the efficacy of 79 per cent.

(This is an unedited and auto-generated story from Syndicated News feed, Fresh Headline Staff may not have modified or edited the content body)

Be the first to comment

Leave a Reply

Your email address will not be published.


*